Cyclophilin B as a co-regulator of prolactin-induced gene expression and function in breast cancer cells

Journal of Molecular Endocrinology

Volumn 44, Issue 6, 2010, Pages 319-329

  Fang, Feng ^b   Zheng, Jiamao ^a   Galbaugh, Traci L ^a   Fiorillo, Alyson A ^a   Hjort, Elizabeth E ^b   Zeng, Xianke ^a   Clevenger, Charles V ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHILIN B; PROLACTIN; SMALL INTERFERING RNA;

ANCHORAGE INDEPENDENT GROWTH; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CELL MOTILITY; CONTROLLED STUDY; DNA MICROARRAY; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CYCLOPHILINS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PROLACTIN; STAT5 TRANSCRIPTION FACTOR;

EID: 77952788767     PISSN: 09525041     EISSN: 14796813     Source Type: Journal    
DOI: 10.1677/JME-09-0140     Document Type: Article

References (59)

1. Beck MT, Peirce SK & Chen WY 2002 Regulation of bcl-2 gene expression in human breast cancer cells by prolactin and its antagonist, hPRL-G129R. Oncogene 21 5047-5055.
2. Brazin KN, Mallis RJ, Fulton DB & Andreotti AH 2002 Regulation of the tyrosine kinase Itk by the peptidyl-prolyl isomerase cyclophilin A. PNAS 99 1899-1904.
3. Breen EC & Tang K 2003 Calcyclin (S100A6) regulates pulmonary fibroblast proliferation, morphology, and cytoskeletal organization in vitro. Journal of Cellular Biochemistry 88 848-854. (Pubitemid 36258834)
4. Brockman JL & Schuler LA 2005 Prolactin signals via Stat5 and Oct-1 to the proximal cyclin D1 promoter. Molecular and Cellular Endocrinology 239 45-53.
5. Brockman JL, Schroeder MD & Schuler LA 2002 PRL activates the cyclin D1 promoter via the Jak2/Stat pathway. Molecular Endocrinology 16 774-784.
6. Clark JW, Snell L, Shiu RP, Orr FW, Maitre N, Vary CP, Cole DJ & Watson PH 1999 The potential role for prolactin-inducible protein (PIP) as a marker of human breast cancer micrometastasis. British Journal of Cancer 81 1002-1008. (Pubitemid 29516144)
7. Clevenger CV, Altmann SW & Prystowsky MB 1991 Requirement of nuclear prolactin for interleukin-2 - stimulated proliferation of T lymphocytes. Science 253 77-79.
8. Clevenger CV, Chang WP, Ngo W, Pasha TL, Montone KT & Tomaszewski JE 1995 Expression of prolactin and prolactin receptor in human breast carcinoma. Evidence for an autocrine/paracrine loop. American Journal of Pathology 146 695-705.
9. Clevenger CV, Furth PA, Hankinson SE & Schuler LA 2003 The role of prolactin in mammary carcinoma. Endocrine Reviews 24 1-27.
10. Clevenger CV, Zheng J, Jablonski EM, Galbaugh TL & Fang F 2008 From bench to bedside: future potential for the translation of prolactin inhibitors as breast cancer therapeutics. Journal of Mammary Gland Biology and Neoplasia 13 147-156.
11. Das R & Vonderhaar BK 1997 Prolactin as amitogen in mammary cells. Journal of Mammary Gland Biology and Neoplasia 2 29-39.
12. Dominguez-Caceres MA, Garcia-Martinez JM, Calcabrini A, Gonzalez L, Porque PG, Leon J & Martin-Perez J 2004 Prolactin induces c-Myc expression and cell survival through activation of Src/Akt pathway in lymphoid cells. Oncogene 23 7378-7390. (Pubitemid 39382140)
13. Eliassen AH, Tworoger SS & Hankinson SE 2007 Reproductive factors and family history of breast cancer in relation to plasma prolactin levels in premenopausal and postmenopausal women. International Journal of Cancer 120 1536-1541.
14. Fang F, Antico G, Zheng J & Clevenger CV 2008 Quantification of PRL/Stat5 signaling with a novel pGL4-CISH reporter. BMC Biotechnology 8 11. (Pubitemid 351420416)
15. Fang F, Flegler AJ, Du P, Lin S & Clevenger CV 2009a Expression of cyclophilin B is associated with malignant progression and regulation of genes implicated in the pathogenesis of breast cancer. American Journal of Pathology 174 297-308.
16. Fang F, Rycyzyn MA & Clevenger CV 2009b Role of c-Myb during PRL-induced Stat5a signaling in breast cancer cells. Endocrinology 150 1597-1606.
17. Fischer G, Tradler T & Zarnt T 1998 The mode of action of peptidyl prolyl cis/trans isomerases in vivo: binding vs. catalysis. FEBS Letters 426 17-20.
18. Fliss MS, Hinkle PM & Bancroft C 1999 Expression cloning and characterization of PREB (prolactin regulatory element binding), a novel WD motif DNA-binding protein with a capacity to regulate prolactin promoter activity. Molecular Endocrinology 13 644-657. (Pubitemid 30636430)
19. Gadd SL & Clevenger CV 2006 Ligand-independent dimerization of the human prolactin receptor isoforms: functional implications. Molecular Endocrinology 20 2734-2746. (Pubitemid 44833532)
20. Ganter B & Giroux CN 2008 Emerging applications of network and pathway analysis in drug discovery and development. Current Opinion in Drug Discovery and Development 11 86-94.
21. Guyette WA, Matusik RJ & Rosen JM 1979 Prolactin-mediated transcriptional and post-transcriptional control of casein gene expression. Cell 17 1013-1023. (Pubitemid 9252308)
22. Hankinson SE, Willett WC, Michaud DS, Manson JE, Colditz GA, Longcope C, Rosner B & Speizer FE 1999 Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women. Journal of the National Cancer Institute 91 629-634. (Pubitemid 29194050)
23. Hu ZZ, Zhuang L, Meng J & Dufau ML 1998 Transcriptional regulation of the generic promoter III of the rat prolactin receptor gene by C/EBPbeta and Sp1. Journal of Biological Chemistry 273 26225-26235. (Pubitemid 28475861)
24. Hunter T 1998 Prolyl isomerases and nuclear function. Cell 92 141-143.
25. Huse M, Chen YG, Massague J & Kuriyan J 1999 Crystal structure of the cytoplasmic domain of the type I TGF beta receptor in complex with FKBP12. Cell 96 425-436. (Pubitemid 29077596)
26. Karnik SK, Chen H, McLean GW, Heit JJ, Gu X, Zhang AY, Fontaine M, Yen MH & Kim SK 2007 Menin controls growth of pancreatic beta-cells in pregnant mice and promotes gestational diabetes mellitus. Science 318 806-809. (Pubitemid 351411773)
27. 2+ homeostasis after ER stress. Journal of Cell Science 121 3636-3648.
28. Kofron JL, Kuzmic P, Kishore V, Colon-Bonilla E & Rich DH 1991 Determination of kinetic constants for peptidyl prolyl cis-trans isomerases by an improved spectrophotometric assay. Biochemistry 30 6127-6134.
29. Leverson JD & Ness SA 1998 Point mutations in v-Myb disrupt a cyclophilin-catalyzed negative regulatory mechanism. Molecular Cell 1 203-211.
30. Lin SY, Yang J, Everett AD, Clevenger CV, Koneru M, Mishra PJ, Kamen B, Banerjee D & Glod J 2008 The isolation of novel mesenchymal stromal cell chemotactic factors from the conditioned medium of tumor cells. Experimental Cell Research 314 3107-3117.
31. Logarajah S, Hunter P, Kraman M, Steele D, Lakhani S, Bobrow L, Venkitaraman A & Wagner S 2003 BCL-6 is expressed in breast cancer and prevents mammary epithelial differentiation. Oncogene 22 5572-5578. (Pubitemid 37102692)
32. Maelandsmo GM, Florenes VA, Mellingsaeter T, Hovig E, Kerbel RS & Fodstad O 1997 Differential expression patterns of S100A2, S100A4 and S100A6 during progression of human malignant melanoma. International Journal of Cancer 74 464-469. (Pubitemid 27400171)
33. Mamane Y, Sharma S, Petropoulos L, Lin R & Hiscott J 2000 Posttranslational regulation of IRF-4 activity by the immunophilin FKBP52. Immunity 12 129-140. (Pubitemid 30398627)
34. Maus MV, Reilly SC & Clevenger CV 1999 Prolactin as a chemoattractant for human breast carcinoma. Endocrinology 140 5447-5450.
35. McHale K, Tomaszewski JE, Puthiyaveettil R, Livolsi VA & Clevenger CV 2008 Altered expression of prolactin receptor-associated signaling proteins in human breast carcinoma. Modern Pathology 21 565-571. (Pubitemid 351589663)
36. Melchior A, Denys A, Deligny A, Mazurier J & Allain F 2008 Cyclophilin B induces integrin-mediated cell adhesion by a mechanism involving CD98-dependent activation of protein kinase C-delta and p44/42 mitogen-activated protein kinases. Experimental Cell Research 314 616-628.
37. Miller SL, Antico G, Raghunath PN, Tomaszewski JE & Clevenger CV 2007 Nek3 kinase regulates prolactin-mediated cytoskeletal reorganization and motility of breast cancer cells. Oncogene 26 4668-4678. (Pubitemid 47067409)
38. Murphy LC, Tsuyuki D, Myal Y & Shiu RP 1987 Isolation and sequencing of a cDNA clone for a prolactin-inducible protein (PIP). Regulation of PIP gene expression in the human breast cancer cell line, T-47D. Journal of Biological Chemistry 262 15236-15241. (Pubitemid 17160185)
39. Murphy LC, Murphy LJ, Tsuyuki D, Duckworth ML & Shiu RP 1988 Cloning and characterization of a cDNA encoding a highly conserved, putative calcium binding protein, identified by an anti-prolactin receptor antiserum. Journal of Biological Chemistry 263 2397-2401. (Pubitemid 18060303)
40. Na SY, Choi JE, Kim HJ, Jhun BH, Lee YC & Lee JW 1999 Bcl3, an IkappaB protein, stimulates activating protein-1 transactivation and cellular proliferation. Journal of Biological Chemistry 274 28491-28496. (Pubitemid 129504718)
41. Nanbu-Wakao R, Fujitani Y, Masuho Y, Muramatu M & Wakao H 2000 Prolactin enhances CCAATenhancer-binding protein-beta (C/EBP beta) and peroxisome proliferator-activated receptor gamma (PPAR gamma) messenger RNA expression and stimulates adipogenic conversion of NIH-3T3 cells. Molecular Endocrinology 14 307-316. (Pubitemid 32295399)
42. Pakula R, Melchior A, Denys A, Vanpouille C, Mazurier J & Allain F 2007 Syndecan-1/CD147 association is essential for cyclophilin B-induced activation of p44/42 mitogen-activated protein kinases and promotion of cell adhesion and chemotaxis. Glycobiology 17 492-503. (Pubitemid 47049937)
43. Pezet A, Favre H, Kelly PA & Edery M 1999 Inhibition and restoration of prolactin signal transduction by suppressors of cytokine signaling. Journal of Biological Chemistry 274 24497-24502. (Pubitemid 129529327)
44. Ren S, Cai HR, Li M & Furth PA 2002 Loss of Stat5a delays mammary cancer progression in a mouse model. Oncogene 21 4335-4339. (Pubitemid 34753841)
45. Robida JM, Nelson HB, Liu Z & Tang H 2007 Characterization of hepatitis C virus subgenomic replicon resistance to cyclosporine in vitro. Journal of Virology 81 5829-5840. (Pubitemid 46847020)
46. Rose-Hellekant TA, Arendt LM, Schroeder MD, Gilchrist K, Sandgren EP & Schuler LA 2003 Prolactin induces ERalpha-positive and ERalpha-negative mammary cancer in transgenic mice. Oncogene 22 4664-4674. (Pubitemid 36976441)
47. Rycyzyn MA & Clevenger CV 2002 The intranuclear prolactin/cyclophilin B complex as a transcriptional inducer. PNAS 99 6790-6795.
48. Rycyzyn MA, Reilly SC, O'Malley K & Clevenger CV 2000 Role of cyclophilin B in prolactin signal transduction and nuclear retrotranslocation. Molecular Endocrinology 14 1175-1186. (Pubitemid 32260479)
49. Scheeren FA, Naspetti M, Diehl S, Schotte R, Nagasawa M, Wijnands E, Gimeno R, Vyth-Dreese FA, Blom B & Spits H 2005 STAT5 regulates the self-renewal capacity and differentiation of human memory B cells and controls Bcl-6 expression. Nature Immunology 6 303-313. (Pubitemid 41724768)
50. Sultan AS, Xie J, LeBaron MJ, Ealley EL, Nevalainen MT & Rui H 2005 Stat5 promotes homotypic adhesion and inhibits invasive characteristics of human breast cancer cells. Oncogene 24 746-760. (Pubitemid 40216084)
51. Tworoger SS, Eliassen AH, Sluss P & Hankinson SE 2007 A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer. Journal of Clinical Oncology 25 1482-1488. (Pubitemid 46733075)
52. Utama FE, LeBaron MJ, Neilson LM, Sultan AS, Parlow AF, Wagner KU & Rui H 2006 Human prolactin receptors are insensitive to mouse prolactin: implications for xenotransplant modeling of human breast cancer in mice. Journal of Endocrinology 188 589-601.
53. Walker SR, Nelson EA & Frank DA 2007 STAT5 represses BCL6 expression by binding to a regulatory region frequently mutated in lymphomas. Oncogene 26 224-233.
54. Wennbo H & Tornell J 2000 The role of prolactin and growth hormone in breast cancer. Oncogene 19 1072-1076. (Pubitemid 30153792)
55. Wennbo H, Kindblom J, Isaksson OG & Tornell J 1997 Transgenic mice overexpressing the prolactin gene develop dramatic enlargement of the prostate gland. Endocrinology 138 4410-4415. (Pubitemid 27408488)
56. Weston K 1999 Reassessing the role of C-MYB in tumorigenesis. Oncogene 18 3034-3038.
57. Yang JM, O'Neill P, Jin W, Foty R, Medina DJ, Xu Z, Lomas M, Arndt GM, Tang Y, Nakada M et al. 2006 Extracellular matrix metalloproteinase inducer (CD147) confers resistance of breast cancer cells to Anoikis through inhibition of Bim. Journal of Biological Chemistry 281 9719-9727. (Pubitemid 43864690)
58. Yurchenko V, O'Connor M, Dai WW, Guo H, Toole B, Sherry B & Bukrinsky M 2001 CD147 is a signaling receptor for cyclophilin B. Biochemical and Biophysical Research Communications 288 786-788.
59. Zheng J, Koblinski JE, Dutson LV, Feeney YB & Clevenger CV 2008 Prolyl isomerase cyclophilin A regulation of Janus-activated kinase 2 and the progression of human breast cancer. Cancer Research 68 7769-7778.